ciprofloxacin has been researched along with Long QT Syndrome in 16 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Ciprofloxacin may cause QTc prolongation and rarely torsades de pointes." | 5.32 | Ciprofloxacin-induced acquired long QT syndrome. ( Krahn, AD; Prabhakar, M, 2004) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "He had a 3." | 1.35 | Ciprofloxacin-induced Q-T interval prolongation. ( Knorr, JP; Moshfeghi, M; Sokoloski, MC, 2008) |
| "Ciprofloxacin may cause QTc prolongation and rarely torsades de pointes." | 1.32 | Ciprofloxacin-induced acquired long QT syndrome. ( Krahn, AD; Prabhakar, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, FA | 2 |
| van Weteringen, W | 1 |
| van der Sijs, H | 2 |
| Hunfeld, NGM | 1 |
| Bunge, JJH | 1 |
| de Groot, NMS | 2 |
| van den Bemt, PMLA | 2 |
| van Gelder, T | 2 |
| Monadian, N | 1 |
| Santbergen, B | 1 |
| Becker, ML | 2 |
| Broers, AEC | 1 |
| Heemskerk, C | 1 |
| Woldman, E | 1 |
| Pereboom, M | 1 |
| Van der Hoeven, R | 1 |
| Mantel-Teeuwisse, A | 1 |
| Van Gemeren, C | 1 |
| Matsuo, K | 1 |
| Fujiwara, K | 1 |
| Omuro, N | 1 |
| Kimura, I | 1 |
| Kobayashi, K | 1 |
| Yoshio, T | 1 |
| Takahara, A | 1 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Salinas Arce, J | 1 |
| Romero, R | 1 |
| Solorzano, P | 1 |
| Werner, CR | 1 |
| Riessen, R | 1 |
| Gregor, M | 1 |
| Bitzer, M | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Kochanek, M | 1 |
| Shimabukuro-Vornhagen, A | 1 |
| Prabhakar, M | 1 |
| Krahn, AD | 1 |
| Letsas, KP | 1 |
| Sideris, A | 1 |
| Kounas, SP | 1 |
| Efremidis, M | 1 |
| Korantzopoulos, P | 1 |
| Kardaras, F | 1 |
| Wooten, JM | 1 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Tsikouris, JP | 1 |
| Peeters, MJ | 1 |
| Cox, CD | 1 |
| Meyerrose, GE | 1 |
| Seifert, CF | 1 |
| Kaźmierczak, J | 1 |
| Peregud-Pogorzelska, M | 1 |
| Rzeuski, R | 1 |
| Knorr, JP | 1 |
| Moshfeghi, M | 1 |
| Sokoloski, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
1 review available for ciprofloxacin and Long QT Syndrome
| Article | Year |
|---|---|
Ciprofloxacin does not Prolong the QTc Interval: A Clinical Study in ICU Patients and Review of the Literature.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Ciprofloxacin; Electrocardiography; Female; Fl | 2017 |
1 trial available for ciprofloxacin and Long QT Syndrome
| Article | Year |
|---|---|
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; | 2006 |
14 other studies available for ciprofloxacin and Long QT Syndrome
| Article | Year |
|---|---|
Dynamics of the QTc interval over a 24-h dose interval after start of intravenous ciprofloxacin or low-dose erythromycin administration in ICU patients.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; El | 2021 |
QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.
Topics: Ciprofloxacin; Drug Therapy, Combination; Electrocardiography; Female; Fluconazole; Heart Rate; Huma | 2018 |
Effects of the fluoroquinolone antibacterial drug ciprofloxacin on ventricular repolarization in the halothane-anesthetized Guinea pig.
Topics: Action Potentials; Anesthesia; Animals; Anti-Bacterial Agents; Calcium Channel Blockers; Ciprofloxac | 2013 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
A case of prolonged QT interval and torsades de pointes due to ciprofloxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Long QT Syndrome; Male; Torsades de Pointes | 2010 |
[Unexpected complication following esophageal variceal hemorrhage - Case 2/2011].
Topics: Amiodarone; Anti-Bacterial Agents; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inh | 2011 |
[53-year-old woman with life-threatening complications after use of ciprofloxacin and posaconazol].
Topics: Anti-Infective Agents; Cardiopulmonary Resuscitation; Ciprofloxacin; Electrocardiography; Female; Hu | 2012 |
Moxifloxacin: new preparation. A me-too with more cardiac risks.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Approval; Fluoroquinolones; France | 2002 |
Ciprofloxacin-induced acquired long QT syndrome.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Electric Countershock; Electrocardiography; Femal | 2004 |
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.
Topics: Aged; Anti-Infective Agents; Antipsychotic Agents; Benzodiazepines; Bundle-Branch Block; Ciprofloxac | 2006 |
Drug-induced QT prolongation.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Electrocardiography; Female; Humans; Long QT Syndrome; O | 2006 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Infective Agents; Ciprofloxacin; Defibrillators, Implantable; Dru | 2007 |
Ciprofloxacin-induced Q-T interval prolongation.
Topics: Abscess; Acetamides; Adolescent; Anti-Infective Agents; Aztreonam; Bradycardia; Ciprofloxacin; Crohn | 2008 |